

THIS IS ZINZINO

Zinzino is a global D2C company from Scandinavia specialising in biomarker-based personalised dietary supplements and health technology. It is a limited liability company with shares listed on the Nasdaq First North Premier Growth Market. The company's test-based and scientifically proven supplements are available in more than 100 markets worldwide. Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company's head office is located in Gothenburg, Sweden, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia and India.

A BRIEF HISTORY

- 2007 Zinzino AB was started. The company's principal business is to own and develop companies in direct sales and related activities.
- 2009 Zinzino Nordic AB was acquired partly through a directed non-cash share issue to the owners of Zinzino Nordic AB and partly through a subscription in the preferential rights issue that Zinzino Nordic AB carried out in December. Through this, Zinzino AB obtained control over 97% of the votes and 92% of the capital of Zinzino Nordic AB. By 31 December 2020, participating interest had increased to 93% of capital.
- 2010 Zinzino shares were listed for trading on the Aktietorget stock market.
- 2011 The group was expanded with companies in Estonia and Lithuania.
- 2012 Companies were started in Latvia and Iceland.
- 2013 A company was started in the US.
- 2014 The group was further expanded by companies in Poland and the Netherlands. In the same year, Zinzino AB acquired BioActive Foods AS and 85% of the shares in Faun Pharma AS. Zinzino AB was listed for trading on Nasdaq OMX First North.
- 2015 A company was started in Canada and the ownership share in Faun Pharma AS was increased to 98.8%.
- 2016 A subsidiary was started in Germany.

 Sales were launched in all of the EU countries.
- 2017 Sales were launched in Switzerland.
- 2018 New subsidiaries in Romania and Italy.
- 2019 New subsidiaries in Australia and India.
- 2020 Acquisition of VMA Life in Singapore.
 Zinzino AB moves up to the premier segment of the
 Nasdaq First North Premier Growth Market.
- 2021 Sales were launched in South Africa.





ZINZINO CONTINUES TO GROW WITH

A STRONG INCREASE IN PROFITABILITY



Dag Bergheim Pettersen, CEO, Zinzino

Zinzino continues to grow and with increased profitability. The third quarter of 2021 is strong, with revenues up by 11% while profitability increases at a fantasic rate.

Needless to say, we are very pleased with the continued strong performance which allows us to stand by our upwardly revised EBITDA forecast for the full year. At the same time, we have had a slightly lower growth rate in the last few months as we matched this year's revenues with our very strong second half of 2020. In view of this, we are now downgrading our revenue target for 2021 to total revenue exceeding at least SEK 1.3 billion for the full year. This still corresponds to a forecast growth of at least 14% for the full year 2021.

FOCUS ON GROWTH, NEW MARKETS, PRODUCT DEVELOPMENT AND E-COMMERCE

We have had a slightly flatter growth curve in recent months compared to the growth rate of the previous 18 months. We remain a growth company with a target to increase our revenues at least 20% annually. We have a clear focus on achieving this both in the current year and in the future. We are launching new markets, new products and continuously improving our e-commerce platform to achieve long-term goals. In conjunction with all this, we have also launched promotions towards our distributors to stimulate their activity and thereby accelerate the growth rate going forward.

We have gradually opened up several markets in recent years. In the third quarter of 2021, we started sales in Taiwan, which achieved full market status at Zinzino. In beginning of November, we also opened our first market in Africa with the launch of South Africa on 9 November. In total, we now operate in an entire 40 markets around the world and have a global webshop for an additional 65 countries. With good forward planning, we have a long-term establishment strategy that is both sustainable and balanced.

Zinzino is building a strong brand in test-based supplements and we are developing high quality products through our own production unit. During the quarter, we launched two new products through our new Vitamin D Test and a magnesium and vitamin D product we call ZinoShine+. Extensive studies at a global level show that people all over the world are very committed to their health. This has become a global trend, not least because of the current pandemic. This gives us a strong belief in the future as safe and sustainable solutions in preventive health care are increasingly in demand.

Digitalisation and the increase in online shopping are also a growing global trend that we're greatly benefiting from, which we're seeing in our sales growth and healthy profitability. Zinzino has already invested and will continue to invest significant capital and resources in e-commerce.



Cape Town, Lions Head, South Africa

AMBITIOUS GOALS

Our vision is to inspire people all over the world to improve their lives and our goal is to have 20 million customers by 2035. A stated milestone of reaching 1 million customers by 2025, which we believe we will reach sooner as we already have over 380,000 customers in our customer register. It's a constant balancing act of working towards our long-term visions and clear goals and doing a good job on a daily basis. I expect that every quarter going forward will be at least as good as the last and that we will continue to deliver good results on both the top and bottom line of our reports.

Our strategy is clear to everyone involved with Zinzino; employees, distributors and suppliers alike. We work with a structured and process-oriented approach with the aim of implementing all our strategic plans. The plans for this and next year are to develop our web tools, launch a number of new products and open in even more markets. We are also looking for potential companies to acquire or invest in to strengthen our continued global growth. Profitable growth is one of our key strategic goals and what really inspires me to push the company forward.

Dag Bergheim Pettersen

CEO Zinzino Inspire Change in Life

FINANCIAL SUMMARY (SEK MILLION)

Key group figures	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Total revenue	313.6	281.8	969.4	798.2	1,138.6
Net sales	296.5	265.6	915.9	751.3	1,074.4
Sales growth	11%	51%	21%	49%	48%
Gross profit	107.5	81.2	313.8	238.3	348.6
Gross profit margin	34.3%	28.8%	32.4%	29.9%	30.6%
Operating profit before depreciation and amortisation	40.4	28.8	111.1	71.1	108.5
Operating margin before depreciation and amortisation	12.9%	10.2%	11.5%	8,9%	9.5%
Adjusted operating profit before depreciation and amortisation*	40.4	28.8	111.1	48.9	86.3
Adjusted operating margin before depreciation and amortisation*	12.9%	10.2%	11.5%	6.1%	7.6%
Operating profit	34.8	22.9	95.1	55.6	86.6
Operating margin	11.1%	8.1%	9.8%	7.0%	7.6%
Profit/loss before tax	34.6	21.6	94.4	53.9	85.0
Net profit	28.2	17.0	75.2	42.3	66.3
Net margin	9.0%	6.0%	7.8%	5.3%	5.8%
Net earnings per share after tax before dilution, SEK	0.80	0.50	2.15	1.25	1.96
Net earnings per share after tax at full dilution, SEK	0.77	0.48	2.05	1.19	1.88
Cash flow from operating activities	23.5	12.0	94.0	64.5	97.3
Cash and cash equivalents	182.9	113.1	182.9	113.1	143.2
Equity/assets ratio	24.4%	15.6%	24.4%	15.6%	19.6%
Equity per share before dilution, SEK	4.01	2.08	4.04	2.08	2.88
Number of issued shares on average for the period	33,695,678	33,042,595	33,502,412	32,798,453	32,860,203
Average number of issued shares for the period with full dilution	35,100,145	34,533,804	35,089,961	34,414,937	34,300,203

^{*}For comparative figures for January-September 2020 and the full year 2020, gross profit, operating profit before and after depreciation/amortisation are affected by SEK 22.2 million through changed accounting as a result of changed terms for distributor remuneration. Net profit was affected by SEK 17.4 million.

ZINZINO'S OUTLOOK AND FINANCIAL GOALS FOR 2021

The Board of Directors of Zinzino adjusts the expected revenues for the full year 2021 to exceed SEK 1,300 (1,139) million, which is lower than the previous revenue forecast of SEK 1,400 million, which was communicated in connection with the report for the first half of 2021. This is due to a slightly weaker growth trend so far in the second half of 2021. At the same time, the expected EBITDA margin for the full year is adjusted once more by 1 percentage point to instead amount to between 9% -12%. However, the Board notes that uncertainty remains regarding Covid-19 and volatile exchange rate changes.

The average growth in sales at Zinzino for the period 2021-2023 will be a minimum of 20% and operating margin before the depreciation/amortisation will increase to over 9%. The dividend policy shall be at least 50% of the free cash flow, as long as liquidity and the equity/assets ratio permit.



SIGNIFICANT EVENTS

DURING AND AFTER THE THIRD QUARTER 2021




Zinzino Vitamin D Concept with ZinoShine+ and Vitamin D Test.

LAUNCH OF NEW VITAMIN D TESTING CONCEPT

On 22 October, Zinzino launched a new product concept for vitamin D with the introduction of the new products Vitamin D Test and ZinoShine+. Vitamin D Test is a dry blood test that anonymously analyses a person's vitamin D status.

The analysis is carried out by Vitas Analytical Services – an independent GMP-certified laboratory in Norway that is a world leader in dry blood testing. Based on the results, advice is provided on whether the person should increase, decrease or maintain their vitamin D status.

As the absorption of vitamin D from the sun is influenced by both seasonal and individual factors, Zinzino recommends continuous testing of vitamin D status. In order to adjust vitamin D intake based on these tests, Zinzino has developed ZinoShine+, an all-natural dietary supplement containing vegan vitamin D $_3$ combined with magnesium. The dose of 12.5 mcg vitamin D $_3$ per tablet allows for an individualised vitamin D intake to maintain optimal vitamin D levels all year round.



Kaohsiung, Taiwan.

TAIWAN ACHIEVES FULL MARKET STATUS

On 9 September 2021, sales started in Taiwan under its own flag as the province achieved full market status. The establishment in Taiwan was made possible by the strategic acquisition of VMA Life by Zinzino in 2020. This was a transition from managing via the global webshop which has acted as a bridge for customers and distributors during the establishment process. The expanded launch gives customers and distributors in Taiwan access to a locally adapted and translated website, printed marketing materials in the local language, as well as an improved logistics solution and a range of payment options.

Taiwan is ranked tenth in the world for total direct sales, making this a very important strategic launch for Zinzino. With the launch in Taiwan, Zinzino will be available in over 100 markets. Zinzino will continue to develop best practices based on the experience gained during previous establishment processes, thus adapting its operations and achieving rapid growth in new markets.

SALES START IN SOUTH AFRICA ON 9 NOVEMBER 2021

During the quarter, Zinzino has continued to work on the establishment processes in a large number of markets and the next country in line is South Africa. It will be the company's first establishment on the African continent. After a thorough and intensive establishment process, sales under the local flag in South Africa started on 9 November 2021, which was celebrated via a simultaneous digital launch event.


Zinzino has been working on the establishment in South Africa for several years. With the help of an industry consultant, a local organisation has been built up which, at the start of sales, consisted of 285 distributors and a customer base of around 3,000 customers. The logistics are handled via a 3PL solution, in South Africa via the provider Expeditors in Johannesburg. Customer support will be handled from the head office in Gothenburg together with the industry consultant who joined Zinzino in the third quarter of 2021 as sales manager for South Africa and the entire African continent.

2021 **Q3** SALES AND PROFIT


SALES Q3

Total revenues for the third quarter of 2021 amounted to SEK 313.6 (281.8) million, corresponding to a growth of 11% compared to the corresponding period last year.

GROWTH PER REGION Q3 2021 VS Q3 2020



SALES PER REGION Q3



COUNTRIES IN REGIONS:

NORDIC COUNTRIES

Denmark, Faroe Islands, Finland, Iceland, Norway, Sweden

BALTIC COUNTRIES Estonia, Latvia, Lithuania

CENTRAL EUROPE

Austria, Germany, Switzerland

EASTERN EUROPE

Czech Republic, Slovakia, Hungary, Poland, Romania

SOUTHERN & WESTERN EUROPECyprus, France, Greece, Italy, Netherlands, Spain, UK

NORTH AMERICA Canada, USA

Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

NORDIC COUNTRIES

In the Nordic countries, total revenues decreased by 12% to SEK 84.4 (95.7) million in the third guarter of 2021 compared to the same period last year. The main reason for the decline in revenues in the third quarter was the slowdown in partner activity over the summer following the cancellation of another in-person event that normally attracts up to 2,000 of the Nordic distributors. However, the decline in revenues from new subscriptions was well offset by the high proportion of subscription sales from the large existing customer bases in the mature markets of the region. The sales manager for the Nordic countries, together with the rest of the team, will continue to support the Nordic markets from the head office with sales and marketing activities. During the fourth quarter, there will be a strong focus on local events where the new vitamin D concept will be introduced in order to attract new customers and distributor groups.

Faun Pharma AS, the Group's subsidiary and manufacturing unit, combined high internal and external production during the quarter, resulting in external sales increasing by 8% to SEK 13.9 (12.8) million compared to the same period last year.

Overall, total revenues in the Nordic countries, Zinzino and Faun combined, accounted for 31% (38%) of the Group's total revenues in the third quarter of 2021.

THE BALTIC COUNTRIES

In the Baltic countries, revenues increased by 8% to SEK 16.6 (15.4) million in the third quarter of 2021 compared to the same period last year. The somewhat weaker sales growth in the quarter is mainly due to the fact that distributors in Latvia and Estonia did not respond to the quarter's sales promotions as expected, which slowed down distributor activity. In Latvia, however, revenues were supported by high subscription sales from the large existing customer base. In Lithuania, high distributor activity and good sales growth combined with high subscription sales from existing customers continued. Overall, the Baltic countries accounted for 5% (5%) of the group's total revenues in the third quarter of 2021.

To stimulate distributor activity, the head office supports the local sales organisations in the relatively mature markets of the region. A number of local events, in the form of both digital and in-person marketing activities focusing on the new product concept, are planned for the fourth quarter.



SALES PER PRODUCT SEGMENT Q3 RESULTS AND FINANCIAL POSITION Q3 The Zinzino Health product segment increased by 13% to SEK 276.7 (245.0) million and represented 88% (87%) RESULTS of total revenue. The Zinzino Coffee product area Gross profit for the third quarter of 2021 amounted decreased by 26% to SEK 5.8 (7.8) million, which correto SEK 107.5 (81.2) million and gross profit margin sponded to 2% (3%) of total revenue. External sales to 34.3% (28.8%). Overall margin improvement on in Faun Pharma AS increased by 9% compared to the goods sold combined with lower remuneration levels corresponding period last year, following combined to distributors were the main factors behind the high internal and external production during the profitability improvement on a gross basis in the third quarter, and amounted to SEK 13.9 (12.8) million, quarter of 2021 compared with the same period in corresponding to 4% (4%) of total revenues. Other the previous year. revenue amounted to SEK 17.2 (16.2) million, which corresponded to the remaining 6% (6%) of revenue **SEK million** EBITDA % for the third quarter of 2021. 350 14% 300 12% Sales **313.6** (281.8) 250 10% 200 8% 150 100 SALES PER PRODUCT AREA Q3 50 03 2018 03 2019 03 2020 03 2021 ■ Total revenue ■ Gross profit ■ EBITDA margin Operating profit before depreciation/amortisation HEALTH 2021; SEK 276,7 (245.0) million COFFEE 2021; SEK 5.8 (7.8) million amounted to SEK 40.4 (28.8) million. The Group's EBITDA margin increased to 12.9% (10.2%). The margin improvement was achieved through economies of scale, mainly through improved efficiency in IT systems, logistics and the organisation as a whole. Operating profit amounted to SEK 34.8 (22.9) million and the operating margin to 11.1% (8.1%). Profit before 2021; SEK 17.2 (16.2) million 2021; SEK 13.9 (12.8) million tax totalled SEK 34.6 (21.6) million and net profit was SEK 28.2 (17.0) million. **DEPRECIATION AND AMORTISATION** Depreciation and amortisation for the quarter were charged to the profit for the period in the amount of SEK 5.6 (5.9) million, of which SEK 0.5 (0.3) million was depreciation of tangible fixed assets and SEK 5.1 (5.6) million was amortisation of intangible fixed assets. Of this, SEK 3.9 (3.6) million is depreciation of right of use assets in accordance with IFRS 16 and SEK 0.2 (0) million is amortisation of licenses attributable to the acquisition of VMA.




2021 | **Q1-Q3** SALES AND PROFITS


SALES Q1-Q3

Total revenues for the first nine months of 2021 amounted to SEK 969.4 (798.2) million, representing a growth of 21% compared to the same period last year.

GROWTH PER REGION Q1-Q3 2021 VS Q1-Q3 2020



SALES PER REGION Q1-Q3



COUNTRIES IN REGIONS:

NORDIC COUNTRIES

Denmark, Faroe Islands, Finland, Iceland, Norway, Sweden

BALTIC COUNTRIES

Estonia, Latvia, Lithuan<u>i</u>a

CENTRAL EUROPE

Austria, Germany, Switzerland

EASTERN EUROPE

Czech Republic, Slovakia, Hungary, Poland, Romania

SOUTHERN & WESTERN EUROPECyprus, France, Greece, Italy, Netherlands, Spain, UK

NORTH AMERICA Canada, USA

Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

NORDIC COUNTRIES

In the Nordic countries, total revenues decreased by 6% to SEK 271.2 (287.4) million in the first nine months compared to the same period last year. This follows sales growth in the Norwegian market, while performance was slightly weaker in Denmark and Sweden. There, revenues have decreased marginally so far this year compared to the corresponding period in 2020. The Finnish market has seen a consistently weaker trend in 2021, losing ground compared to the previous year. Zinzino has been focusing on the Finnish distributors and has taken steps to re-stimulate growth in the country. As a result, partner activity has picked up again and the decline in revenues has slowed in recent months. The downturn has continued in Iceland with low distributor activity and a reduced customer base so far this year.

Faun Pharma AS, the Group's subsidiary and manufacturing unit, combined high internal and external production during the year, resulting in external sales increasing by 12% to SEK 47.3 (42.2) million compared to the same period last year.

Overall, total revenues in the Nordic countries, Zinzino and Faun combined, accounted for 33% (41%) of the Group's total revenues in Q1-Q3 2021.


BALTIC COUNTRIES

In the Baltic countries, total Q1-Q3 2021 cumulative revenues increased by 7% to SEK 52.2 (48.8) million compared to the same period last year. The growth was mainly attributable to Lithuania, where the trend continued with high partner activity and an influx of new customers. On the other hand, there was a slight decline in sales in Latvia, where revenue came mainly from the high proportion of repeat purchases of the company's products by existing customers. The decline has also continued in Estonia with low distributor activity so far this year. The region's total revenues represented 5% (6%) of the Group's total revenues in Q1-Q3 2021.


CENTRAL EUROPE

Continued good growth in the DACH region during the year, where the experienced distributor organisations operate with high efficiency and a strong focus on the positive effects of the products. Through the work of the distributors, the region has built a strong customer base with a strong interest in health that continues to grow. In Q1-Q3 2021, cumulative revenues increased by 29% compared to SEK 162.5 (125.9) million following generally high activity among distributors. This represented 17% (16%) of the Group's total revenues in Q1-Q3 2021.











GROUP REPORT SUMMARY OF FINANCIAL POSITION

Amounts in SEK thousands	01/07/2021 30/09/2021	01/07/2020 30/09/2020	01/01/2021 30/09/2021	01/01/2020 30/09/2020	01/01/2020 31/12/2020
Net sales	296,529	265,607	915,910	751,320	1,074,448
Other revenue	16,562	16,153	52,730	46,426	63,707
Own work capitalised	526	85	740	490	490
Goods for resale and other direct costs	-206,126	-200,677	-655,610	-559,912	-790,090
Gross profit	107,491	81,168	313,770	238,324	348,555
External operating expenses	-35,763	-27,883	-105,769	-93,905	-134,926
Personnel costs	-31,313	-24,440	-96,877	-73,320	-105,093
Depreciation/amortisation	-5,566	-5,898	-15,999	-15,477	-21,958
Operating profit	34,849	22,947	95,125	55,622	86,578
Net financial income/expense	-298	-1,366	-720	-1,759	-1,563
Tax	-6,350	-4,624	-19,195	-11,568	-18,689
PROFIT/LOSS FOR THE PERIOD	28,201	16,957	75,210	42,295	66,326
of foreign subsidiaries Other comprehensive profit/loss for the period	626 626	268 268	2,643 2,643	-4,942 -4,942	-5,546 -5,546
Currency exchange differences upon conversion	•				
TOTAL COMPREHENSIVE PROFIT/LOSS					
FOR THE PERIOD	28,827	17,225	77,853	37,353	60,780
Profit/loss for the period attributable to:					
Parent company's shareholders	27,011	16,663	71,869	41,112	64,477
Non-controlling interest	1,190	294	3,341	1,183	1,849
TOTAL	28,201	16,957	75,210	42,295	66,326
Total comprehensive profit/loss for the period att	ributable to:				
Parent company's shareholders	27,637	16,931	74,512	36,170	58,931
Non-controlling interest	1,190	294	3,341	1,183	1,849
TOTAL	28,827	17,225	77,853	37,353	60,780
Earnings per share, calculated on the profit/loss fo	or the period att	ributable to 1	the parent co	mpany's shar	eholders:
Amounts in SEK	or the period att	ributable to t	the parent co	mpany's shar	eholders:
	or the period att	0.50	the parent co	mpany's shar	eholders: 1.96

GROUP REPORT SUMMARY OF FINANCIAL POSITION

Amounts in SEK thousands	30/09/2021	30/09/2020	31/12/2020
Fixed assets			
Goodwill	39,267	37,543	36,593
Other intangible fixed assets	20,480	21,300	19,225
Equipment, tools and installations	9,229	7,086	6,831
Right-of-Use Assets	40,393	39,129	43,553
Financial fixed assets	4,840	4,250	3,698
Total fixed assets	114,209	109,308	109,900
Current assets			
Inventories	170,066	128,584	126,949
Current receivables	50,113	53,430	66,536
Pre-paid costs and accrued revenues	36,837	33,205	36,791
Cash and bank balances	182,926	113,137	143,218
Total current assets	439,942	328,356	373,493
TOTAL ASSETS	554,151	437,664	483,394
Equity			
Share capital	3,370	3,304	3,305
Other contributed capital	35,595	23,660	27,507
Retained earnings including profit/loss for the period	96,286	41,113	63,851
Total equity	135,251	68,077	94,663
Long-term liabilities			
Leasing liabilities	25,804	29,444	34,012
Deferred tax liability	1,302	-	-
Other long-term liabilities	5,702	5,833	5,329
Total long-term liabilities	32,808	35,277	39,341
Current liabilities			
Accounts payable	32,170	44,428	54,686
Tax liabilities	14,725	6,642	12,311
Leasing liabilities	15,461	10,119	10,119
Other current liabilities	214,486	165,518	163,007
Accrued costs and deferred revenues	109,250	107,603	109,267
Total current liabilities	386,092	334,310	349,390

GROUP REPORT SUMMARY OF CHANGES IN EQUITY

Amounts in	Share	Ongoing rights	Other contributed	Conversion	•		Non- controlling	Total
SEK thousands	capital	issue	capital	reserves	the period	Total	interest	Equity
Opening balance								
01/01/2020	3,258	-	12,804	1,435	15,520	33,017	7,271	40,287
Profit/loss for the period	-	-	-	-	41,112	41,112	1,183	42,295
Other comprehensive								
profit/loss for the period	-	-	-	-5,836	-	-5,836	-	-5,836
Change of the minority	-	-	-	-	1,822	1,822	-1,822	-
Rights issue	46	8	10,856	-	-	10,910	-	10,910
Issued warrants	-	-	-	-	3,408	3,408	-	3,408
Dividends	-	-	-	-	-22,987	-22,987	-	-22,987
Closing balance 30/09/2020	3,304	8	23,660	-4,401	38,875	61,446	6,632	68,077
Opening balance 01/10/2020	3,304	8	23,660	-4,401	38,875	61,446	6,632	68,077
Profit/loss for the period	-	-		-	23,365	23,365	666	24,031
Other comprehensive								
profit/loss for the period	-	-	-	-871	-	-871	-	-871
Share repurchase	-	-	-	-	-669	-669	-	-669
Change of the minority	-	-	-	-	60	60	-60	-
Rights issue	1	23	3,817	-	-	3,841	-	3,841
Issued warrants	-	-	-	-	254	254	-	254
Closing balance 31/12/2020	3,305	31	27,477	-5,272	61,885	87,426	7,238	94,663
Opening balance	3,305	31	27,477	-5,272	61,885	87,426	7,238	94,663
Profit/loss for the period	-	-	_,,.,,	-	71,869	71,869	3,341	75,210
Other comprehensive					, :=	•	,	•
profit/loss for the period	-	-	-	2,643	-	2,643	-	2,643
Share repurchase	-	-	-	-	-1,329	-1,329	-	-1,329
Change of the minority	-	-	-	-	97	97	-97	-
Rights issue	65	-24	8,112	-	-	8,153	-	8,153
Issued warrants	-	-	-	-	9	9	-	9
Dividends	-	-	-	-	-42,120	-42,120	-1,978	-44,098
Closing balance 30/09/2021	3,370	7	35,589	-2,629	90,411	126,748	8,504	135,251

GROUP REPORT SUMMARY OF CASH FLOWS

Amounts in SEK thousands	01/07/2021 30/09/2021	01/07/2020 30/09/2020	01/01/2021 30/09/2021	01/01/2020 30/09/2020	01/01/2020 31/12/2020
Operating activities					
Profit/loss before financial items	34,849	22,947	95,125	55,622	86,578
Depreciation and amortisation/write-downs	5,566	5,898	15,999	15,477	21,958
Currency fluctuations	655	145	-3,058	1,883	2,679
Total	41,070	28,990	108,066	72,982	111,215
Interest received	84	20	319	80	91
Interest paid	-382	-1,386	-1,039	-1,839	-1,654
Tax paid	-7,301	-2,694	-15,237	-3,837	-4,314
Total	-7,599	-4,060	-15,957	-5,596	-5,877
Cash flow from operating activities before changes in operating capital	33,471	24,930	92,109	67,386	105,338
Cash flow from changes in operating capital					
Change in inventories	-2,473	-23,134	-43,117	-39,720	-36,560
Change in current receivables	-11,416	-17,362	16,377	-53,888	-70,259
Change in current liabilities	3,954	27,531	28,615	90,676	98,793
Total	-9,935	-12,965	1,875	-2,932	-8,026
Cash flow from operating activities	23,536	11,965	93,984	64,454	97,312
Investment activity					
Investments in intangible fixed assets	-1,017	-719	-3,863	-2,412	-2,321
Investments in tangible fixed assets	-1,668	-1,109	-2,986	-1,947	-2,561
Investments in financial fixed assets	-1,055	-3 834	-2,228	-3 834	-4,502
Cash flow from investment activities	-3,740	-5,662	-9,077	-8,193	-9,384
Financing activities					
Amortisation of lease liabilities attributable to	2.705	2.245	44.244	7720	42.424
lease agreements Issuance of options	-3,785 4	-2,245 1,877	-11,241 9	-7,738 1,877	-13,424 2,140
Rights issue	-	1,077	8,153	8,887	12,724
Dividends	_	_	-42,120	-22,987	-22,987
Cash flow from financing activities	-3,781	-368	-45,199	-19,961	-21,547
CASH FLOW FOR THE PERIOD	16,015	5,935	39,708	36,300	66,381
Cash and cash equivalents at start of period	166,911	107,202	143,218	76,837	76,837
Cash and cash equivalents at end of period	182,926	113,137	182,926	113,137	143,218
Change in cash and cash equivalents	16,015	5,935	39,708	36,300	66,381

PARENT COMPANY REPORT SUMMARY INCOME STATEMENT

Amounts in SEK thousands	01/07/2021 30/09/2021	01/07/2020 30/09/2020	01/01/2021 30/09/2021	01/01/2020 30/09/2020	01/01/2020 31/12/2020
Managara	27.270	11 024	70.751	15.660	72.766
Net sales	27,378	11,824	78,751	15,660	73,766
Other revenue	5,825	4,871	18,431	5,314	10,423
Goods for resale and other direct costs	-23,265	-4,182	-71,153	-5,307	-43,768
Gross profit	9,938	12,513	26,029	15,667	40,421
External operating expenses	-6,389	-4,905	-19,288	-11,851	-18,397
Depreciation/amortisation	-161	-102	-449	-279	-421
Operating profit	3,388	7,506	6,292	3,537	21,603
Net financial income/expense and currency	2,432	1,150	3,238	1,010	29,292
Tax	-1,557	-	-1,557	-	-5,067
PROFIT/LOSS FOR THE PERIOD	4,263	8,656	7,973	4,547	45,828

There are no items in the parent company reported as other comprehensive profit/loss, so the total comprehensive profit/loss matches the profit/loss for the period.

PARENT COMPANY REPORT SUMMARY OF FINANCIAL POSITION

Amounts in SEK thousands	30/09/2021	30/09/2020	31/12/2020
Fixed assets			
Intangible fixed assets	3,885	1,380	1,886
Tangible fixed assets	33	-	-
Financial fixed assets	104,246	99,262	100,009
Total fixed assets	108,164	100,642	101,895
Current assets			
Current receivables	777	1,860	57
Intra-group receivables	15,734	15,948	18,200
Pre-paid costs and accrued revenues	2,553	3,168	2,941
Cash and bank balances	5,635	791	7,091
Total current assets	24,699	21,767	28,289
TOTAL ASSETS	132,863	122,409	130,184
Equity			
Restricted equity			
Share capital	3,370	3,304	3,305
Ongoing rights issue	7	-	31
Fund for development expenditures	3,885	1,380	1,886
Unrestricted equity			
Share premium reserve	26,659	32,996	36,808
Retained earnings (including profit/loss for the year)	10,820	-12,058	28,696
Total equity	44,741	25,622	70,726
Long-term liabilities			
Long-term liabilities	5,275	5,393	4,913
Intra-group long-term liabilities	15,476	15,476	15,476
Total long-term liabilities	20,751	20,869	20,389
Current liabilities			
Tax liabilities	1,216	-	5,067
Intra-group current liabilities	56,165	64,364	22,265
Other current liabilities	8,475	10,167	10,866
Accrued costs and deferred revenues	1,515	1,387	871
Total current liabilities	67,371	75,918	39,069

PARENT COMPANY REPORT SUMMARY OF CHANGES IN EQUITY

Amounts in SEK thousands	Share capital	Ongoing rights issue	Fund for development expenditures	Share premium reserve	Retained earnings including profit/loss for the period	Total Equity
Opening balance 01/01/2020	3,258	-	1,129	22,138	2,734	29,259
Profit/loss for the period	-,	-	-		4,547	4,547
Internally generated intangible assets	-	-	251	-	-251	-
Rights issue	46	8	-	10,857	-	10,911
Issued warrants	-	-	-	-	3,892	3,892
Dividends	-	-	-	-	-22,987	-22,987
Closing balance 30/09/2020	3,304	8	1,380	32,995	-12,065	25,622
Opening balance 01/10/2020	3,304	8	1,380	32,995	-12,065	25,622
Profit/loss for the period	-	-	-	-	41,281	41,281
Internally generated intangible assets	-	-	506	-	-506	-
Rights issue	1	23	-	3,813		3,837
Issued warrants	-	-	-	-	-14	-14
Closing balance 31/12/2020	3,305	31	1,886	36,808	28,696	70,726
Opening balance 01/01/2021	3,305	31	1,886	36,808	28,696	70,726
Profit/loss for the period	-	-	-	-	7,973	7,973
Internally generated intangible assets	-	-	1,999	-	-1,999	-
Rights issue	65	-24	-	8,112	-	8,153
Issued warrants	-	-	-	-	9	9
Dividends	-	-	-	-18,261	-23,859	-42,120
Closing balance 30/09/2021	3,370	7	3,885	26,659	10,820	44,741

PARENT COMPANY REPORT SUMMARY OF CASH FLOWS

Amounts in SEK thousands	01/07/2021 30/09/2021	01/07/2020 30/09/2020	01/01/2021 30/09/2021	01/01/2020 30/09/2020	01/01/2020 31/12/2020
Onevating activities					
Operating activities Profit/loss before financial items	3,388	7,506	6,292	3,537	21,603
Depreciation and amortisation/write-downs	3,366 161	102	449	279	,
·					421
Currency fluctuations	193	-827	644	-989	-950
Total	3,742	6,781	7,385	2,827	21,074
Interest received	82	-	455	23	23
Interest paid	-	-	-2	-1	-2
Tax paid	-128	-	-5,408	-	-
Total	-46	-	-4,955	22	21
Cash flow from operating activities before					
changes in operating capital	3,696	6,781	2,430	2,849	21,095
Cash flow from changes in operating capital					
Change in current receivables	4,990	-4,456	2,132	-1,806	-2,029
Change in current liabilities	-7,694	-8,422	32,154	16,523	2,523
Cash flow from operating activities	992	-6,097	36,716	17,566	21,589
Investment activity					
Investments in intangible fixed assets	-491	-	-2,201	-531	-1,179
Investments in tangible fixed assets	-	-	-38	-	-
Investments in financial fixed assets	-167	-3,720	-4,237	-4,339	-5,237
Cash flow from investment activities	-658	-3,720	-6,476	-4,870	-6,416
Financing activities					
Issuance of options	4	22	9	22	8
Rights issue	-	-	8,153	8,887	12,724
Dividends received	2,262	-	2,262	-	-
Dividends	-	-	-42,120	-22,987	-22,987
Cash flow from financing activities	2,266	22	-31,696	-14,078	-10,255
CASH FLOW FOR THE PERIOD	2,600	-9,795	-1,456	-1,382	4,918
Cash and cash equivalents at start of period	3,035	10,586	7,091	2,173	2,173
Cash and cash equivalents at end of period	5,635	791	5,635	791	7,091
Change in cash and cash equivalents	2,600	-9,795	-1,456	-1,382	4,918

NOTE 1

SEGMENT INFORMATION

Description of segments and main activities:

A business segment is part of a company which carries out business activities from which it can obtain revenue and incur costs, the contribution of which is regularly reviewed by the company's highest executive decision-maker, and for which there is independent financial information.

The company's reporting of business segments is in line with the internal reporting to the highest executive decision-maker. The highest executive decision-maker is the position that assesses the earnings of the business segment and decides on the allocation of resources. The CEO is the highest executive decision-maker together with the Group CFO and the controller manager. Together, they form the strategic steering group at Zinzino. The strategic steering group assesses the operations based on the two business segments Zinzino and Faun. The steering group mainly uses profit/loss before financial items in the assessment of business segment earnings. Segment reporting is divided based on the main segment of the business "Zinzino", which includes the product areas Health, Coffee and Other revenue.

The Health product area includes the Balance, Immune Supplement, Skin Care and Weight Control sub-areas. The product area Coffee is also called Beverages and includes espresso machines, coffees, teas and accessories. Other revenue consists mainly of freight and reminder fees. All sales are made via the Zinzino's website www.zinzino.com with the help of the company's independent sales organisation, which goes under the names of distributors or Partners.

The second segment refers to the Norwegian production unit Faun Pharma AS, known as "Faun", which carries out production and sales to external customers not under Zinzino's standard sales concept. Sales from Faun comprise exclusively contract production of food supplements to different customers. The largest external customers include Life and Proteinfabrikken AS. In Q3 and Q4 2020, the VMA Life segment included sales from the operations in Singapore, Malaysia, Taiwan and Thailand that were added in connection with the acquisition of VMA Life. In 2021, sales in these countries were included in the Zinzino segment. The comparative figures for 2020 have been recalculated in accordance with the updated segment structure and VMA Life has been allocated to the Zinzino segment.

Segment revenues and earnings

Total revenues and earnings before financial items is the result metric reported to the strategic steering group at Zinzino. An analysis of the group's revenues and earnings for the two reporting operating segments is set out below:

- Zinzino
- · Faun Pharma AS

The strategic steering group mainly uses adjusted earnings before interest and tax and operating earnings (see below) to assess the business segment profit/loss.

			Group		
July-Sep 2021	Zinzino	Faun	elimination	Total Group	
Net sales	282,629	42,240	-28,340	296,529	
Other revenue	16,562	-	-	16,562	
Own work capitalised	526	-	-	526	
Goods for resale and other direct costs	-206,249	-28,217	28,340	-206,126	
Gross profit	93,468	14,023	-	107,491	
External operating expenses	-34,343	-1,420	-	-35,763	
Personnel costs	-24,218	-7,095	-	-31,313	
EBITDA	34,907	5,508	-	40,415	
Depreciation/amortisation	-4,318	-1,248	-	-5,566	
Operating profit	30,589	4,260	-	34,849	

			Group	
July-Sep 2020	Zinzino	Faun	elimination	Total Group
Net sales	252,775	39,986	-27,154	265,607
Other revenue	16,153	-	-	16,153
Own work capitalised	85	-	-	85
Goods for resale and other direct costs	-199,431	-28,400	27,154	-200,677
Gross profit	69,582	11,586	-	81,168
External operating expenses	-26,346	-1,537	-	-27,883
Personnel costs	-18,065	-6,375	-	-24,440
EBITDA	25,171	3,674	-	28,845
Depreciation/amortisation	-4,650	-1,248	-	-5,898
Operating profit	20,521	2,426	-	22,947

Jan-Sep 2021	Zinzino	Faun	Group elimination	Total Group
Net sales	868,654	137,994	-90,738	915,910
Other revenue	52,730	-	· -	52,730
Own work capitalised	740	-	-	740
Goods for resale and other direct costs	-651,615	-94,733	90,738	-655,610
Gross profit	270,509	43,261	-	313,770
External operating expenses	-100,376	-5,393	-	-105,769
Personnel costs	-77,579	-19,298	-	-96,877
EBITDA	92,554	18,570	-	111,124
Depreciation/amortisation	-12,241	-3,758	-	-15,999
Operating profit	80,313	14,812	-	95,125
Jan-Sep 2020	Zinzino	Faun	Group elimination	Total Group
Net sales	709,087	108,552	-66,319	751,320
Other revenue	46,426	-	-	46,426
Own work capitalised	490	-	-	490
Goods for resale and other direct costs	-549,859	-76,372	66,319	-559,912
Gross profit	206,144	32,180	-	238,324
External operating expenses	-89,383	-4,522	-	-93,905
Personnel costs	-56,576	-16,744	-	-73,320
EBITDA	60,185	10,914	-	71,099
Depreciation/amortisation	-11,725	-3,752	-	-15,477
Operating profit	48,460	7,162	-	55,622
Inn Dos 2020	Zinzino	Faun	Group elimination	Total Group
Jan-Dec 2020 Net sales	1,014,525	149,685	-89,762	1,074,448
Other revenue	63,707	-	-	63,707
Own work capitalised	490	_	_	490
Goods for resale and other direct costs	-775,225	-104,627	89,762	-790,090
Gross profit	303,497	45,058	-	348,555
External operating expenses	-128,031	-6,895	-	-134,926
Personnel costs	-80,659	-24,434	-	-105,093
EBITDA	94,807	13,729	-	108,536
Depreciation/amortisation	-17,082	-4,876	-	-21,958
Operating profit	77,725	8,853	-	86,578

NOTE 2 **NET TURNOVER**

Revenues

Sales between segments are carried out on market terms. As revenue from external parties is reported to the strategic steering group, they are valued in the same way as in the group's statement of comprehensive profit/loss.

Goods within Zinzino Health and Zinzino Coffee refer to sales to Zinzino's customers and distributors in the various sales markets through the online shop. The goods are sold mainly through subscriptions which run for a fixed period of 6 months and continue indefinitely until the customer terminates the subscription. All revenues are recognised when the goods are delivered to the customer in accordance with IFRS 15.

For more information regarding the products, see note 2.5.1 in the annual report 2020 regarding the principles of revenue recognition.

External goods Faun refers to goods produced on contract for an external customer. Revenue is recognised when the goods are delivered to the customer in accordance with IFRS 15, see note 2.5.1 in the 2020 annual report on revenue recognition principles.

Events and other services refer to revenue in connection with distributor conferences.

July-Sep 2021	Zinzino	Faun	Total Group
Net sales	282,629	13,900	296,529
Revenue from external customers	282,629	13,900	296,529
Goods within Zinzino Health	276,691	-	276,691
Goods within Zinzino Coffee	5,916	-	5,916
Sales of external goods Faun	-	13,900	13,900
Events and other services	22	-	22
TOTAL	282,629	13,900	296,529
July-Sep 2020	Zinzino	Faun	Total Group
Net sales	252,775	12,832	265,607
Revenue from external customers	252,775	12,832	265,607
Goods within Zinzino Health	244,946	-	244,946
Goods within Zinzino Coffee	7,829	-	7,829
Sales of external goods Faun	-	12,832	12,832
TOTAL	252,775	12,832	265,607

Jan-Sep 2021	Zinzino	Faun	Total Group
Net sales	868,654	47,256	915,910
Revenue from external customers	868,654	47,256	915,910
Goods within Zinzino Health	847,851	-	847,851
Goods within Zinzino Coffee	19,565	-	19,565
Sales of external goods Faun	-	47,256	47,256
Events and other services	1,238	-	1,238
TOTAL	868,654	47,256	915,910
Jan-Sep 2020	Zinzino	Faun	Total Group
Net sales	709,086	42,234	751,320
Revenue from external customers	709,086	42,234	751,320
Goods within Zinzino Health	686,098	-	686,098
Goods within Zinzino Coffee	22,988	-	22,988
Sales of external goods Faun	-	42,234	42,234
TOTAL	709,086	42,234	751,320
Jan-Dec 2020	Zinzino	Faun	Total Group
Net sales	1,014,525	59,923	1,074,448
Revenue from external customers	1,014,525	59,923	1,074,448
Goods within Zinzino Health	981,389	-	981,389
Goods within Zinzino Coffee	30,762	-	30,762
Sales of external goods Faun	-	59,923	59,923
Events and other services	2,374	-	2,374
TOTAL	1,014,525	59,923	1,074,448

NOTE 3

TRANSACTIONS WITH RELATED PARTIES

	July-Sep	July-Sep	Jan-Sep	Jan-Sep	Jan-Dec
Purchase of goods and services	2021	2020	2021	2020	2020
Saele Invest & Consulting AS*	7,989	7,903	25,236	23,706	32,463
Oh Happy Day Aps**	1,509	1,559	4,999	4,455	6,067
TOTAL	9,498	9,462	30,235	28,161	38,530
	July-Sep	July-Sep	Jan-Sep	Jan-Sep	Jan-Dec
Sales of goods and services	2021	2020	2021	2020	2020
Sæle Invest & Consulting AS	-	-	-	-	-
Oh Happy Day ApS***	-	-	-	437	437
TOTAL	-	-	-	437	437

As of 30/09/2021, the debt to Saele Invest & Consulting AS relating to sales commissions amounts to SEK 0 (0) thousand and to Oh Happy Day ApS to SEK 0 (0) thousand in the Group. All sales commissions paid to related parties with significant influence are calculated on the same commission plan and under the same terms as for all other distributors within Zinzino's global sales organisation.

^{*} Refers to sales commissions to/purchases from Saele Invest & Consulting AS which is controlled by Örjan Saele and who, through the company's shareholding in Zinzino AB, is defined as a person with significant influence.

^{**} Refers to sales commissions to Oh Happy Day, which is controlled by Peter Sörensen and who, through the company's shareholding in Zinzino AB, is defined as a person with significant influence.

^{***} Remuneration according to agreement for 75% of the company's establishment costs in Australia 2019/2020 from Oh Happy Day ApS. The receivable from the company as of 30/09/2021 amounts to SEK 2,398 (2,851) thousand.

NOTE 4 EARNINGS PER SHARE

	July-Sep	July-Sep	Jan-Sep	Jan-Sep	Jan-Dec
SEK	2021	2020	2021	2020	2020
Earnings per share before dilution	0.80	0.50	2.15	1.25	1.96
Earnings per share after dilution	0.77	0.48	2.05	1.19	1.88
Earnings metric used in the calculation of earnings per share					
Earnings attributable to shareholders of the parent company used in the calculation of earnings per share before and after dilution	27,011	16,663	71,869	41,112	64,477
Number of shares					
Weighted average number of ordinary shares in calculating earnings per share before dilution	33,695,678	33,042,595	33,502,412	32,798,453	32,860,203
Adjustment for calculation of earnings per share after dilution (of warrants)					
Weighted average number of ordinary shares and potential ordinary shares used as denominator in calculating earnings per share after dilution	35,100,145	34,533,804	35,089,961	34,414,937	34,300,203

NOTE 5

EVENTS AFTER THE END OF THE INTERIM PERIOD

No significant events for the company have occurred after the end of the reporting period as at 30 September 2021.

NOTE 6

FINANCIAL METRICS NOT DEFINED IN ACCORDANCE WITH IFRS

The company presents certain financial metrics in the interim report that are not defined in accordance with IFRS or the Annual Accounts Act. The company believes that these metrics provide valuable additional information to investors and the company's management as they allow the company's performance to be

evaluated. Since not all companies calculate financial metrics in the same way, these are not always comparable with the metrics used by other companies. These financial metrics should therefore not be considered as a substitute for metrics defined in accordance with IFRS.

ALTERNATIVE KEY FIGURES	DEFINITION	PURPOSE
Sales growth	The total revenue as a percentage change compared with the total revenue for the corresponding period of the previous year.	This metric is useful to follow as it shows the sales trend in the group.
Gross profit	Profit from total revenue less goods for resale.	This metric is useful to examine to see just the net sales during the period, which can be used in the income and cost analyses.
EBITDA	Operating profit before depreciation/ amortisation and write-downs.	This metric is relevant for creating an understanding of the company's operational business, regardless of financing and depreciation of fixed assets.
EBITDA margin:	EBITDA as a percentage of total revenues for the period.	This metric is relevant to create an understanding of operational profitability and as the metric excludes depreciation, this margin gives the stakeholders a clearer picture of the company's central profitability.
Operating profit/loss (EBIT)	Operating profit/loss before financial items and taxes.	This metric illustrates profitability regard- less of the tax rate for corporation tax and irrespectiveof the company's financial structure.
Net margin	Profit/loss for the period as a percentage of total revenues for the period.	This metric illustrates the company's profitability.
Equity per share before dilution	Equity in relation to the number of outstanding shares on the balance sheet date.	This metric measures the company's net value per share and shows whether the company is increasing the shareholders' capital over time.
Cash flow from operating activities	Cash flow from operational business including changes in the operating profit/loss.	This metric measures the cash flow the company generates before capital investments and cash flow attributed to the company's financing.
Equity/assets ratio	Equity in relation to the balance sheet total.	This metric is an indicator of the company's leverage to finance the company.
Adjusted EBITDA and Adjusted EBITDA margin	The definition of key figures described above, excluding items affecting comparability.	The metric is important for breaking down and creating an understanding of the effect regarding items affecting comparability.
Items affecting comparability	Items affecting comparability are reported separately in the financial statements when this is necessary to explain the group's results. "Items affecting comparability" means significant revenue or expense items that are reported separately due to the significance of their nature or amount.	The metric is significant for creating an understanding of items affecting comparability.

GOTHENBURG, 19 NOVEMBER 2021

The Board and the CEO certify that the report for the period 1 January – 30 September 2021 gives a fair overview of the parent company and group's operations, position and earnings and describes significant risks and uncertainties faced by the parent company and the companies in the group.

For more information, please call Dag Bergheim Pettersen, Chief Executive Officer, Zinzino AB.

Zinzino AB

Hulda Mellgrens gata 5 421 32 Västra Frölunda Email: info@zinzino.com Tel: +46 (0)31-771 71 50 Gothenburg, 19 November 2021

Hans Jacobsson

Board Chair

Pierre Mårtensson

Board Member

Ingela Nordenhav
Board Member

Staffan Hillberg

Board Member

Anna FrickBoard Member

Dag Bergheim Pettersen
Chief Executive Officer

AUDITOR'S REPORT

Introduction

We have performed a review of the summary interim financial information of Zinzino AB as of 30 September 2021 and the nine-month period ended on that date. The Board of Directors and the CEO are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34 and the Swedish Financial Reporting Act. Our responsibility is to express a conclusion on this interim report based on our review.

Focus and scope of the review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410 Review of Interim Financial Information Performed by the Company's Selected Auditor. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical review, and performing other review procedures. A review has a different focus and a much smaller scope compared to the focus and scope of an audit under ISA and generally accepted auditing standards. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified if an audit had been carried out. Therefore, the stated conclusion based on a review does not have the assurance that a stated conclusion based on an audit has.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information has not been prepared, in all material respects, in accordance with IAS 34 and the Annual Accounts Act for the Group and in accordance with the Annual Accounts Act for the Parent Company.

Gothenburg, 19 November 2021 Öhrlings Pricewaterhousecoopers AB

Fredrik Göransson

Authorised auditor

